2010-feb-09
NO WEBCAST
2/9-2/10
Keck
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: A Workshop
The National Cancer Policy Forum held a public workshop addressing the widening spectrum of precompetitive collaboration in oncology biomedical research and development. Over the last decade, biomedical research and drug development costs have skyrocketed, despite falling productivity evidenced by increasing drug development timelines and decreasing new molecular entity approvals. Increased precompetitive collaboration is a potential driver for innovation and improved productivity. Recent developments in the field of biomedical research and drug development, including the implementation of one-on-one consortia, network models, and larger scale consortia highlight the increasing role that competitive and precompetitive collaboration is assuming within biomedical research and drug development.
Workshop presentations and discussions provided a general characterization of the precompetitive collaboration environment, as well as examples of precompetitive collaboration in science, biomedicine, and oncology. The concluding panel was devoted to exploring how we can leverage prior experiences to facilitate future precompetitive collaboration opportunities.
The Roundtable on Translating Genomic-Based Research for Health hosted a related workshop in July 2010 in Washington, D.C.
Confirmed Speakers
· Jill Altshuler, M.B.A., AltshulerGray
· Neal Cohen, M.D., M.P.H., M.S., University of California, San Francisco School of Medicine
· Gregory Curt, M.D., AstraZeneca and CEO Roundtable on Cancer Life Sciences Consortium
· Laura Esserman, M.D., M.B.A., UCSF Carol Franc Buck Breast Care Center
· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Pearl Huang, Ph.D., Merck & Co., Inc.
· Gary Kelloff, M.D., NCI Cancer Imaging Program
· Karim Lakhani, Ph.D., M.S., Harvard Business School
· Mark McClellan, M.D., Ph.D., Brookings Institution’s Engelberg Center for Health Care Reform
· Bernard Munos, M.B.A., Ph.D., Eli Lilly & Co.
· William Spencer, Ph.D., Chairman Emeritus, SEMATECH
· Joseph Vockley, Ph.D., The Cancer Genome Atlas
· David Wholley, M. Phil., The Biomarkers Consortium
· Thinh Nguyen, J.D., Science Commons
· Bryn Williams-Jones, Pfizer
· Ray Woosley, M.D., Ph.D., Critical Path Institute
Planning Committee
· John Wagner, M.D., Ph.D., Merck & Co., Inc. (Chair)
· Anna Barker, Ph.D., National Cancer Institute
· Stephen Eck, M.D., Ph.D., Eli Lilly & Co.
· Stephen Friend, M.D., Ph.D., Sage Bionetworks
· Geoff Ginsburg, M.D., Ph.D., Duke University
· Roy Herbst, M.D., Ph.D., MD Anderson
· Sharon Murphy, M.D., IOM Scholar-in-Residence